FDA makes the final call
Borensztein is a triple board-certified endocrinologist and obesity specialist with same-week appointments available in Collingswood, NJ Have questions about getting started, managing side effects, or figuring out which medication is right for you
MHRA Borderline Guidance MHRA guidance updated on 2 July 2026 explains that classification can consider pharmacological properties, explicit and implied claims, intended purpose, packaging, websites, social-media content and customer reviews
In 2023, the FDA designated BPC-157 as a Category 2 bulk drug substance, meaning it cannot be compounded by commercial pharmaceutical companies, and there is insufficient evidence regarding potential harm to humans
Those with known allergy to B12 or cobalt should avoid
When managed early, the Blahs dont need to derail treatment